NEW YORK (GenomeWeb News) – Rosetta Genomics said yesterday that it has completed its previously announced direct offering of approximately $5.1 million in securities.

Rosetta has received net proceeds of approximately $4.5 million after deducting placement agent fees and other offering expenses.

The molecular diagnostics developer said that it plans to use the $4.5 million in proceeds from the offering for general corporate purposes and to support the development of its microRNA-based diagnostic pipeline.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.

Dec
04
Sponsored by
Sophia Genetics

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.

Dec
11
Sponsored by
PerkinElmer

This webinar describes a study that used two independent next-generation sequencing (NGS) platforms to gain insight into the impact of different types of aneuploidies during preimplantation genetic testing.

Dec
12
Sponsored by
Illumina

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.